Launch Metrics Dashboard: What to Track in First 12 Months

The first twelve months after a pharmaceutical product launch are a period of intense scrutiny. Executive leadership, investors, and the board all want to know whether the launch is on track. Yet many brand teams struggle to define what "on track" actually means, resulting in either information overload (too many metrics, no clarity) or dangerous blind spots (tracking the wrong things).

This article provides a structured launch metrics framework organized by phase, priority, and function. It is designed to help brand teams build a launch dashboard that answers the three questions that matter most: Are we growing? Are we efficient? Are we building sustainable competitive advantage?

The Three Phases of Launch Measurement

Launch metrics should be organized into three distinct phases, each with different focal areas and reporting cadences. The metrics that matter in month one are not the same as those that matter in month nine.

Phase 1: Awareness and Trial (Months 1-3)

The first 90 days after launch are about generating awareness among target HCPs and converting that awareness into initial trial prescriptions. The metrics in this phase are predominantly leading indicators: they predict future prescribing behavior rather than measuring current revenue.

Prescription Metrics

In the first quarter, the key prescription metrics are total prescriptions (TRx), new prescriptions (NRx), and the ratio between them. For a new brand, NRx should dominate the TRx count, ideally representing 70-85% of total volume. A declining NRx-to-TRx ratio early in launch suggests that new prescriber acquisition is slowing while refills have not yet ramped, which is a warning sign.

• TRx Volume: Total prescription count, tracked weekly. Expect a gradual ramp from near-zero in week one to an inflection point around weeks 8-12 for primary care launches, or weeks 4-8 for specialty launches with pre-built awareness.
• NRx Volume: New prescriptions are the leading indicator of prescriber adoption. Track NRx at the individual prescriber level to identify early adopters and laggards.
• New-to-Brand (NBRx): New-to-brand prescriptions exclude switches from other products within your portfolio. This is the purest measure of competitive share gain.
• Prescriber Count: The number of unique prescribers writing at least one prescription. Track weekly and set targets by specialty segment.

Field Force Activity

Field force metrics in the first quarter focus on reach and activity levels. The most important metric is call plan completion rate: what percentage of target HCPs have received at least one detail in the first 30, 60, and 90 days. Top-quartile launch teams achieve 80% call plan completion in month one.

Digital Engagement

Digital metrics in the first quarter measure HCP awareness and interest. Key metrics include HCP website visits, approved email open and click rates, eSampling requests, and digital ad impressions. Track digital engagement at the individual HCP level and correlate with field force activity to identify HCPs who are engaging across multiple channels.

Expect approved email open rates of 25-35% during launch (higher than steady-state due to novelty). HCP website traffic should ramp quickly in weeks 2-4 as field force referrals drive digital visits. eSampling conversion rates in the first quarter typically range from 15-25% depending on therapeutic area.

Phase 2: Adoption and Growth (Months 4-6)

By month four, the launch transitions from awareness building to adoption acceleration. The metrics shift from activity-based leading indicators to outcome-based metrics that measure whether the brand is gaining real traction in the market.

Market Share Metrics

Market share is the definitive measure of launch success. Track market share at the total market level and by key segments (specialty, geography, payer class). Month 4-6 share targets vary by therapeutic area and competitive intensity, but the following benchmarks provide reference points.

Managed Care Coverage

Payer coverage is a critical enabler of prescribing velocity. Track the percentage of covered lives by formulary tier, the percentage of lives with unrestricted access (no prior auth or step therapy), and the average copay differential versus competitors. By month six, strong launches typically have 50-65% of commercial lives covered on tier 2 or better.

• Formulary win rate: Percentage of targeted payers that have placed the brand on a favorable tier. Target 60%+ by month 6.
• Prior authorization rate: Percentage of prescriptions requiring PA. Lower is better. Benchmark: 30-50% for specialty drugs at month 6.
• Time to PA approval: Average days from PA submission to decision. Target under 3 business days.
• Copay card utilization: Percentage of patients activating the copay card. Benchmark: 40-60% activation rate.

Patient Funnel Metrics

The patient funnel measures the progression from prescription written to patient on therapy. Track the following conversion rates: prescription written to dispensed (fulfillment rate), dispensed to second fill (early persistency), and second fill to third fill (continuation). Drop-off at any stage signals access barriers, affordability issues, or lack of patient support.

Benchmarks for patient funnel conversion in the launch year: prescription to dispensed 65-80%, dispensed to second fill 60-75%, second fill to third fill 70-85%. Brands with dedicated patient hub services typically achieve 10-15 percentage points higher fulfillment rates.

Phase 3: Optimization and Scale (Months 7-12)

ROI by Channel

By month seven, there is enough data to begin assessing channel-level ROI. This requires integrating prescription data with channel exposure data (field calls, emails, digital impressions, events, samples) at the individual HCP level. The goal is to understand which channels are driving prescribing and which are consuming budget without proportional impact.

Competitive Defense Metrics

By months 7-12, competitors will have had time to respond to your launch with counter-detailing, formulary negotiations, and competitive messaging. Track competitive metrics including: share shifts among competing brands, HCP switching behavior (from competitor to your brand and vice versa), competitive counter-detail frequency, and win/loss analysis on key formulary decisions.

Persistency and Adherence

Patient persistency becomes measurable around month six, when enough patients have been on therapy long enough to assess drop-off patterns. Track 90-day persistency (percentage of patients still on therapy at day 90), mean days on therapy, and medication possession ratio (MPR). Early persistency benchmarks vary widely by therapeutic area, but a 90-day persistency rate below 60% is a red flag for most chronic therapies.

Building Your Launch Dashboard

A launch metrics dashboard should be more than a collection of charts. It should tell a story about launch health and surface actionable insights. The best dashboards share these characteristics: they have no more than 8-12 primary metrics, they use color coding (green/yellow/red) to indicate performance against target, they include both leading (activity) and lagging (outcome) indicators, and they are updated at a frequency that matches decision-making cadence.

The dashboard should be accessible to the entire cross-functional launch team, including brand marketing, field force leadership, market access, medical affairs, and analytics. Weekly operational reviews should cover Tier 1 metrics in a 30-minute stand-up format. Monthly strategic reviews should cover all tiers with deep dives into any metric trending yellow or red.

Launch excellence is not about having the most data. It is about having the right data, at the right time, organized to drive the right decisions. Build your dashboard before launch day, validate the data feeds in the first two weeks, and iterate on the metrics as your launch evolves through its first year.